BioBlock nasal spray had a publication in a PLOS ONE scientific journal
The scientific journal PLOS ONE has published an article with extensive information on antibodies to SARS-CoV-2 derived from bovine colostrum. Efficiency, safety and relevance data have been shared. During the time of pandemic, that has affected us all, this article is of great importance. Information is available on the entire concept, as well as on possible implementation measures to develop safe and effective products as an alternative additional measure to combat the spread of the virus.
BioBlock nasal spray, which has received a lot of recognition and support, contains antibodies to SARS-CoV-2 derived from bovine colostrum. This is thoroughly reviewed in the article. The ability of the antibodies to neutralize all known strains of SARS-CoV-2, including the current omicron strain, is also described.
Why is publishing this article important? The renowned scientific journals check the entire content very carefully before publication. Everything must be proven! Publication in a scientific journal confirms what the Estonian team has achieved and introduces the necessary content of this concept.
The full article is available here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268806
The article has been published thanks to the joint effort of Estonian researchers, universities and the companies that created BioBlock. Many thanks to Icosagen Grupp, OÜ Teadus ja Tegu, Estonian University of Life Sciences, University of Tartu and AS Chemi-Pharm.
The virus has not disappeared and, unfortunately, a new rise in infections is expected. BioBlock nasal spray is an effective way to protect yourself.
Backround: A consortium consisting of Icosagen Grupp, AS Chemi-Pharm, University of Tartu (Institute of Pharmacy, Institute of Biomedical and Transplant Medicine and Institute of Technology), Estonian University of Life Sciences (Institute of Veterinary Medicine and Animal Husbandry), and OÜ Teadus ja Tegu have jointly developed technology to create a colostrum preparation to prevent coronavirus infection. The consortium plans to conduct clinical trials in Estonia and launch a nasal and throat spray, “SARS-CoV-2 BioBlock” containing this preparation.
This product is not a drug but an antiviral prophylactic preparation that acts on the surface of the nasopharyngeal mucosa, where it can specifically inactivate the Covid-19 agent SARS CoV-2 virus. SARS-CoV-2 BioBlock nasal and throat spray is not a substitute for vaccination or wearing a mask but is an additional measure to break viral chains. The SARS-CoV-2 BioBlock nasal and throat spray could be helpful wherever social distancing and wearing a mask is difficult: at home, at work, in a restaurant, at school, in sports practice, in a vehicle, and in other crowded places. It is recommended that the product also be used by infected people to reduce the risk of infecting people they are in close contact with. In addition, the preparation can be used to support new, more prevalent virus variants originating from the United Kingdom, South Africa, and Brazil.
For more information, please read: https://www.medihex.com/en/